10-Q · May 14, 2026
Medicus Pharma reported a significant net loss, worsening from $5.1 million in Q4 2025 to $9.0 million in Q4 2026. Despite increased cash reserves from equity financings, the company remains without any revenue,…
Earnings analysis · 10-Q
MDCX earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Medicus Pharma remains a pre-revenue clinical-stage company, with revenue of $0 and Q2 net loss widening to $11,684,427 from $6,176,084 year over year as operating expenses increased 90.8% to $11,478,789. Liquidity…
Read full summary
Medicus Pharma remains a pre-revenue clinical-stage company, with revenue of $0 and Q2 net loss widening to $11,684,427 from $6,176,084 year over year as operating expenses increased 90.8% to $11,478,789. Liquidity improved through $32,354,942 of financing cash flow, but operating cash burn reached $15,953,129 for the first six months and management disclosed substantial going-concern doubt. Clinical and regulatory progress for SkinJect and Teverelix is constructive, but rising R&D needs, new secured debt of $22,864,225, dilution and Nasdaq's $1.00 minimum-bid deficiency keep the risk/reward profile bearish.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.21
What stood out
-
No Revenue; Loss Expanded Year Over Year
Revenue remained $0 because the Company does not currently earn revenue from its drug-development programs. Net loss increased to $11,684,427 in Q2 2026 from $6,176,084 in Q2 2025, while diluted loss per share improved to $(0.21) from $(0.43), reflecting share-count dilution.
-
Operating Costs Increased Sharply
Operating expenses rose 90.8% year over year to $11,478,789 in Q2 2026 from $6,016,088. G&A increased 43.6% to $6,571,097 and R&D increased 241.0% to $4,907,692.
-
Teverelix Drives R&D Investment
Six-month R&D expense increased 120.9% to $7,612,085 from $3,445,778, primarily due to Teverelix development. Management expects R&D expenses to increase further as two separate Teverelix Phase 2 trials advance.
-
SkinJect Clinical and Regulatory Progress
SkinJect's Phase 2 SKNJCT-003 dataset showed 55% histological clearance and 64% clinical clearance in the 200-microgram cohort. The FDA also authorized the Gorlin Syndrome Phase 2b study to proceed on July 27, 2026.
-
Teverelix Study Size Reduced
The redesigned Teverelix AUR study is expected to enroll approximately 126 patients, down from approximately 390 patients under the prior development plan, supporting an earlier pharmacodynamic signal and dose optimization.
-
Financing Increased Liquidity
Cash and cash equivalents increased to $15,174,128 at June 30, 2026 from $8,705,218 at December 31, 2025, while restricted cash was $10,017,412. Financing activities generated $32,354,942 during the first six months.
What to watch
-
High Cash Burn and Going-Concern Risk
The Company used $15,953,129 in operating cash during the first six months, up from $9,409,825 in the prior-year period. Management states that substantial doubt exists about the Company's ability to continue as a going concern within one year after the financial statements are issued.
-
New Secured Debt Raises Leverage
The May 27, 2026 financing added secured promissory notes with original principal of $22,864,225, including Note A at 8.75% interest and Note B at 5% interest, both maturing November 27, 2027. The notes are secured by company and subsidiary assets, including intellectual property.
-
Nasdaq Minimum-Bid Delisting Risk
Nasdaq notified the Company that its closing bid price had been below $1.00 for 30 consecutive business days. The Company has until October 19, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
-
Persistent Losses and No Profitability
The Company had an accumulated deficit of $85,007,966 at June 30, 2026 and reported a six-month net loss of $20,726,738. Management expects significant operating losses for the foreseeable future and may never become profitable.
-
Substantial Equity Dilution
The Company issued 28,248,981 shares under its ATM through June 30, 2026 for gross proceeds of $12,868,181, and had 60,168,044 shares outstanding at quarter-end. Continued equity financing may dilute existing shareholders.
-
Clinical and Funding Execution Risk
Management identifies trial failure, inability to obtain FDA authorization for later-stage development, and inability to secure funding as principal risks. R&D expense was already $7,612,085 for the first six months, with additional spending expected for two Teverelix Phase 2 trials.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects significant operating losses for the foreseeable future and expects R&D expenses to increase as two Teverelix Phase 2 trials advance.
Earlier filings 4
10-K · April 29, 2026
Medicus Pharma's annual report indicates a focus on positioning itself within the pharmaceutical industry through innovative product development and market expansion. However, the company reported a challenging year…
10-K · March 25, 2026
Medicus Pharma is a clinical-stage, multi-strategy biotech focused on two core assets: SkinJect's doxorubicin microneedle array (D-MNA) for basal cell carcinoma (BCC) and Antev's Teverelix for prostate-related…
10-K · March 28, 2025
Medicus Pharma Ltd. (MDCX) is a pre-revenue biotech focused on a single product candidate, SkinJect (a doxorubicin tip‑loaded dissolvable microneedle array) for basal cell carcinoma. The Phase 1 program completed in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.